08:26 AM EDT, 08/26/2024 (MT Newswires) -- BridgeBio Pharma ( BBIO ) said Monday it is collaborating with the Cardiovascular Data Science, or CarDS, Lab at Yale School of Medicine to address the underdiagnosis of transthyretin amyloid cardiomyopathy, or ATTR-CM.

The study will deploy CarDS Lab's artificial intelligence-powered tools, such as AI-electrocardiography, AI-point-of-care ultrasound, and AI-echocardiography, across US health systems' electronic health records to identify individuals with potentially missed ATTR-CM, BridgeBio said.

The research will be presented at the European Society of Cardiology's Congress 2024, the company said.

Price: 25.03, Change: -0.28, Percent Change: -1.11